AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31116017
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment control condition
Trial: 16201937
Drug: Meropenem (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (500 mg IV q8h)
Trial: 16201937
Drug: Imipenem-cilastatin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem-cilastatin (500 mg IV q8h)
Trial: 12899226
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg doxazosin daily for 3 months
Trial: 10599899
Drug: Usual activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual activities of daily living (Control group)
Trial: 8566836
Drug: Acetyl salicylic
RxNorm normalized name: Acetyl salicylic acid specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl salicylic acid (ASA) 650 mg three times daily
Trial: 8566836
Drug: Effervescent calcium
RxNorm normalized name: Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent calcium carbasalate (ECC) 826.8 mg three times daily
Trial: 2011771
Drug: d-penicillamine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-penicillamine (500 mg/day)
Trial: 27306620
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg apixaban twice daily (n=9120)
Trial: 27306620
Drug: Warfarin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (target INR range 2.0-3.0; n=9081)
Trial: 18807583
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg tablet formulation A
Trial: 18807583
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg tablet formulation B
Trial: 16297323
Drug: Reduced Glutathione
RxNorm normalized name: Reduced glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced Glutathione (GSH) 1.2 g/d through intravenous drip for 7 days
Trial: 10100041
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + metronidazole tabs 200 mg tds for 7 days
Trial: 10100041
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + 2 subgingival applications of 25% metronidazole gel
Trial: 85106
Drug: Bay g
RxNorm normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bay g 6575 (1.2 g daily for 1 week)
Trial: 85106
Drug: Bay g
RxNorm normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bay g 6575 (1.2 g single dose)
Trial: 85106
Drug: Bay g
RxNorm normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bay g 6575 and dipyridamole (combined administration)
Trial: 85106
Drug: Bay g
RxNorm normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bay g 6575 (alone)
Trial: 27583214
Drug: Aminobisphosphonate solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminobisphosphonate solution
Trial: 20059657
Drug: Dynamic infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dynamic infusion cavernosometry and cavernosography (DICC)
Trial: 11753000
Drug: 0.07 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 mg/kg neostigmine administered upon reappearance of the first tactile TOF response (group I)
Trial: 11753000
Drug: 0.07 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 mg/kg neostigmine administered upon reappearance of the second tactile TOF response (group II)
Trial: 11753000
Drug: 0.07 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 mg/kg neostigmine administered upon reappearance of the third tactile TOF response (group III)
Trial: 11753000
Drug: 0.07 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 mg/kg neostigmine administered upon reappearance of the fourth tactile TOF response (group IV)
Trial: 11753000
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not explicitly defined, but implied as no neostigmine administration)
Trial: 2283012
Drug: PGE2‐gel (Prepidil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2‐gel (Prepidil) intravaginal
Trial: 17277392
Drug: Anti-vascular endothelial
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-vascular endothelial growth factor agents
Trial: 26957836
Drug: New pharmacologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New pharmacologic agents
Trial: 24328907
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate 0.1% cream (BMVc)
Trial: 24328907
Drug: Tacrolimus 0.1%
RxNorm normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.1% ointment (TACo)
Trial: 22521875
Drug: 100mg hydrocortisone
RxNorm normalized name: hydrocortisone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg hydrocortisone given as a rapid intravenous bolus
Trial: 16328453
Drug: intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intradermal injection of 50 microg capsaicin without cooling
Trial: 16328453
Drug: injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of capsaicin followed by application of 0 degrees C cold pain stimulation
Trial: 1473164
Drug: Allylestrenol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allylestrenol (30 mg/d initially, reduced to 5 mg/d after 15 days)
Trial: 1473164
Drug: Lynestrenol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lynestrenol (10 mg/d initially, reduced to 1.25 mg/d)
Trial: 6143138
Drug: Maintenance of
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance of activity, anti-inflammatory and antirheumatic drugs, and systemic steroids where necessary
Trial: 6143138
Drug: Rest and
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rest and anti-inflammatory and antirheumatic drugs
Trial: 30559259
Drug: Sutimlimab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutimlimab (10 mg/kg test dose followed by 60 mg/kg full dose 1 to 4 days later and 3 additional weekly doses of 60 mg/kg)
Trial: 27797093
Drug: Selective Spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective Spinal Lidocaine (SS-L): 3 mL of 0.8% lidocaine solution (24 mg lidocaine, 15 μg fentanyl)
Trial: 27797093
Drug: Conventional Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Dose Lidocaine (CD-L): 5 mL of 1% lidocaine solution (50 mg lidocaine, 25 μg fentanyl)
Trial: 25361563
Drug: PCPPP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCPPP treatment group
Trial: 18060250
Drug: Antithrombotic pharmacobiologic
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic pharmacobiologic therapy
Trial: 16128945
Drug: Bi-weekly endoscopic
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bi-weekly endoscopic variceal ligation (EVL)
Trial: 16128945
Drug: Bi-monthly endoscopic
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-monthly endoscopic variceal ligation (EVL)
Trial: 12401580
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg bolus followed by a 4 mg/min infusion during operation and 4 mg/kg in the priming solution of CPB)
Trial: 7798579
Drug: Low-fat controlled
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat controlled diet plus 20 g corn bran supplement
Trial: 7798579
Drug: Low-fat controlled
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat controlled diet plus 20 g wheat bran supplement
Trial: 2086820
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (CXM-AX) 250 mg t.i.d. for 3-7 days
Trial: 2086820
Drug: Cefaclor (CCL)
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor (CCL) 250 mg t.i.d. for 3-7 days
Trial: 765515
Drug: 600,000 units
RxNorm normalized name: Wycillin, 600,000 units/mL intramuscular suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600,000 units of penicillin G benzathine
Trial: 765515
Drug: 1.2 million
RxNorm normalized name: penicillin G benzathine 1.2 million unit INTRAMUSC VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 million units of penicillin G benzathine
Trial: 765515
Drug: 600,000 units
RxNorm normalized name: Wycillin, 600,000 units/mL intramuscular suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600,000 units of penicillin G benzathine and 600,000 units of penicillin G procaine
Trial: 765515
Drug: 900,000 units
RxNorm normalized name: Bicillin C-R 900/300, 900,000 units-300,000 units/2 mL intramuscular suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900,000 units of penicillin G benzathine and 300,000 units of penicillin G procaine
Trial: 24118640
Drug: Linagliptin 2.5
RxNorm normalized name: linagliptin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 2.5 mg plus metformin 1000 mg bid
Trial: 24118640
Drug: Linagliptin 2.5
RxNorm normalized name: linagliptin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 2.5 mg plus metformin 500 mg bid
Trial: 24118640
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg bid
Trial: 24118640
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg bid
Trial: 31297968
Drug: Linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 5 mg qd
Trial: 15102334
Drug: Response to
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response to treatment as a predictor of LOS
Trial: 15102334
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT) as a predictor of LOS
Trial: 2998786
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Metoprolol (beta 1‐selective)
Trial: 2998786
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg Propranolol (non‐selective)
Trial: 28820949
Drug: Synthetic cartilage
RxNorm normalized name: SHARK CARTILAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic cartilage implant MTPJ1 hemiarthroplasty
Trial: 24499493
Drug: NRL001 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRL001 5 mg, 7.5 mg, or 10 mg in 1 or 2 g suppositories
Trial: 24499493
Drug: NRL001 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRL001 10 mg, 12.5 mg, or 15 mg in 1 or 2 g suppositories
Trial: 24499493
Drug: NRL001 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRL001 doses (1 g and 2 g)
Trial: 24499493
Drug: NRL001 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRL001 doses
Trial: 19345644
Drug: EVT 201
RxNorm normalized name: EVT 201
DrugBank: EVT 201 (DB05721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVT 201 1.5 mg
Trial: 19345644
Drug: EVT 201
RxNorm normalized name: EVT 201
DrugBank: EVT 201 (DB05721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVT 201 2.5 mg
Trial: 17351300
Drug: Sprinkles 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprinkles 12.5 mg ferrous fumarate
Trial: 17351300
Drug: Sprinkles 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprinkles 20 mg ferrous fumarate
Trial: 17351300
Drug: Sprinkles 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprinkles 30 mg ferrous fumarate
Trial: 17351300
Drug: Sprinkles 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprinkles 20 mg micronized ferric pyrophosphate
Trial: 17351300
Drug: DROPS 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DROPS 20 mg ferrous glycine sulphate
Trial: 15364158
Drug: Preprandial dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preprandial dosing of BIAsp 30 (b.i.d. injections before meals)
Trial: 15364158
Drug: Postprandial dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial dosing of BIAsp 30 (b.i.d. injections after meals)
Trial: 15364158
Drug: Postprandial dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial dosing of BIAsp 30
Trial: 15364158
Drug: Preprandial dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preprandial dosing of BIAsp 30
Trial: 15364158
Drug: Postprandial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial injection
Trial: 11454372
Drug: Low-dose combined
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combined spinal epidural (n=351)
Trial: 11454372
Drug: Low-dose infusion
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose infusion epidural (n=350)
Trial: 11454372
Drug: Low-dose techniques
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose techniques
Trial: 11454372
Drug: Low-dose infusion
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose infusion group
Trial: 9498439
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (60-mg retinol equivalent, 200,000 IU)
Trial: 7989683
Drug: Infiltration anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration anesthesia administered into the incised edges of the wound
Trial: 7989683
Drug: Infiltration anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration anesthesia administered into the skin surrounding the wound
Trial: 2563896
Drug: Intravenous metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoprolol (15 mg immediately, followed by oral metoprolol)
Trial: 2563896
Drug: Deferred oral
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Deferred oral beta-blockade (started on day 6)
Trial: 25556976
Drug: Aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole once-monthly (AOM) 400 mg
Trial: 25556976
Drug: Oral aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral aripiprazole (6-24 mg/day)
Trial: 17117016
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg twice a day
Trial: 9272926
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (IB) via pressurized metered-dose inhaler (pMDI)
Trial: 24335055
Drug: 800 IU
RxNorm normalized name: Vitamin E 800 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 IU (20 μg) vitamin D₃
Trial: 24335055
Drug: 2000 IU
RxNorm normalized name: D 2000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU (50 μg) vitamin D₃
Trial: 24335055
Drug: 4000 IU
RxNorm normalized name: Cholecalciferol 4000 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 IU (100 μg) vitamin D₃
Trial: 23099311
Drug: Implicit dosage
RxNorm normalized name: Empliciti
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Implicit dosage interval (6 ML by mouth every 12 hours)
Trial: 23099311
Drug: Explicit dosage
RxNorm normalized name: Empliciti
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Explicit dosage interval (6 ML by mouth at 7 AM and 7 PM)
Trial: 20145273
Drug: High-dose imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose imatinib (800 mg/day for 6 months followed by 400 mg/day as maintenance therapy)
Trial: 22511495
Drug: Standard-dose imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose imatinib (400 mg/day)
Trial: 10664054
Drug: dimenhydrinate suppositories
RxNorm normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dimenhydrinate suppositories
Trial: 8878241
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg on Day 1, followed by 5 mg/kg once daily for 4 days)
Trial: 8878243
Drug: Amoxicillin/clavulanate (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (approximately 40 mg/kg/day in 3 divided doses for 10 days)
Trial: 1985163
Drug: Simultaneous continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous continuous infusions of MTX and VM‐26
Trial: 1985163
Drug: Sequential continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential continuous infusions of MTX and VM‐26
Trial: 31234639
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors and β-blockers
Trial: 28691885
Drug: Fitusiran (0.225,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitusiran (0.225, 0.45, 0.9, or 1.8 mg/kg or fixed dose of 80 mg, once monthly)
Trial: 28691885
Drug: Fitusiran (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitusiran (0.03 mg/kg, single subcutaneous injection)
Trial: 28691885
Drug: Fitusiran (0.015,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitusiran (0.015, 0.045, or 0.075 mg/kg, once weekly)
Trial: 28691885
Drug: Fitusiran (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitusiran (once monthly)
Trial: 23364237
Drug: Sarpogrelate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate (100 mg, tid)
Trial: 28898204
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg, qd)
Trial: 12112177
Drug: Sertraline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (100 mg OD)
Trial: 10025743
Drug: Atopy Patch
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopy Patch Test (APT) with 3000 to 10,000 PNU/g of Dermatophagoides pteronyssinus, cat dander, grass, birch, and mugwort pollen allergen extracts in petrolatum
Trial: 8703659
Drug: Inhaled magnesium
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled magnesium sulphate (0, 90, 135, 180, 360 mg)
Trial: 16444382
Drug: Norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (400 mg daily)
Trial: 101316
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (800 mg/day for 1 week or a single dose of 1.0 g by mouth)
Trial: 101316
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (by inhalation)
Trial: 7058674
Drug: Arginine aspartate
RxNorm normalized name: Arginine aspartate
DrugBank: Arginine aspartate (DB15993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arginine aspartate (250 mg/dg/day for one week)
Trial: 26965174
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU); n=89
Trial: 25253174
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg/bid)
Trial: 22731240
Drug: Ondansetron in
RxNorm normalized name: ondansetron Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron in combination with dexamethasone
Trial: 20831698
Drug: Eltrombopag 75
RxNorm normalized name: eltrombopag 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 75 mg q.i.d.
Trial: 18159905
Drug: Potent topical
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent topical steroids
Trial: 16129209
Drug: Low-calcium session
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calcium session (L-HF) with calcium ion concentration of 2.5 mEq/L (1.25 mmol/L)
Trial: 16129209
Drug: High-calcium session
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calcium session (H-HF) with calcium ion concentration of 3.5 mEq/L (1.75 mmol/L)